Treatment of recurrent Paget's disease of the vulva with topical bleomycin.
Seven patients with recurrent Paget's disease of the vulva underwent treatment with topical bleomycin (NSC 125066-Blenoxane, Bristol Laboratories) ointment. None had an associated invasive carcinoma. Four patients experienced a complete, objective response to this therapy, and one of these has responded completely to treatment of a subsequent recurrence. In two patients the response could not be evaluated. All patients experienced pain in the treated area; one, developed systemic toxicity to bleomycin requiring cessation of therapy. Topical bleomycin appears to benefit selected patients with recurrent Paget's disease of the vulva.
D000287:Administration, Topical; D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010145:Paget Disease, Extramammary / Q000188:drug therapy*; D010146:Pain / Q000139:chemically induced; D012008:Recurrence; D012075:Remission, Spontaneous; D014846:Vulvar Neoplasms / Q000188:drug therapy*
D001761:Bleomycin